Recently, Dorayshield announced another milestone in its overseas nuclear medicine protective equipment expansion: 25pcs 5cc tungsten alloy syringe shields were successfully delivered to a medical equipment supplier in Azerbaijan. These shields will be used in the supplier's radiopharmaceutical injection equipment, providing safety protection for nuclear medicine staff at local hospitals. This marks the company's official entry into the Central Asian medical market and further expands its international reach.
The 5cc tungsten alloy syringe shields exported are core protective components developed by Dorayshield for clinical nuclear medicine injection scenarios. These shields are made of high-purity tungsten alloy. With a tungsten content over 97% and a density of 18.5g/cm³, it achieves a radiation shielding efficiency of over 99.6% which means it completely blocks and mitigates the risks of gamma radiation at the source. During the injection of radiopharmaceuticals like iodine-131 and technetium-99m, the drugs release dangerous radiation for the medical staff. These products are specifically designed for 5cc syringes and have a smooth, burr-free interior. This allows secure placement of the syringes, as well as ease of adjustable dosing in the 5cc range for ease of grip. It is 30% lighter than traditional lead shields, which makes it even easier to use. Additionally, the anti-corrosion treated surface allows for high-frequency disinfection, as it withstands medical alcohol, iodine, and harsh disinfectants, preventing rust and deformation. It provides excellent corrosion resistance, which is essential for hospital use.
The collaboration originated from the quality expectations of an Azerbaijani supplier, as stated by the head of the medical device division of the company. This supplier has been providing nuclear medicine equipment to the country's public hospitals. Their old shields had problems with shielding instability and difficult functionality. Medical staff feedback indicated the need for improvements to the design of the shields. This supplier, after learning about Dorayshield from an international medical equipment exhibition, bought three samples for clinical trials. The three-month trial resulted in medical staff acclaim for the shield's protective performance and ease of use, which culminated in the order of 25 units.
This export to Azerbaijan not only marks the first breakthrough for Dorayshield nuclear medicine protection products in the Central Asian market, but also provides valuable experience in serving emerging markets. Going forward, the company will continue to optimize its shielding product line, developing compatible models for syringes of varying specifications. Furthermore, it will deepen collaboration with medical clients in Central Asia, Eastern Europe, and other regions, providing safer and more efficient radiation protection solutions to medical institutions worldwide and helping to enhance the safety of nuclear medicine diagnosis and treatment.
